We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+14.89%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.59B
AUM Growth
+$163M
(+6.7%)
Cap. Flow
-$639M
Cap. Flow
% of AUM
-24.64%
Top 10 Holdings %
Top 10 Hldgs %
35.1%
Holding
118
New
11
Increased
13
Reduced
28
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$84.6M |
| 2 |
McKesson
MCK
|
+$33.5M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$32.2M |
| 4 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$20.7M |
| 5 |
Bausch Health
BHC
|
+$20.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$102M |
| 2 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$61.7M |
| 3 |
AERI
Aerie Pharmaceuticals
AERI
|
+$46.5M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$31.5M |
| 5 |
Humana
HUM
|
+$26.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.12% |
| 2 | Financials | 2.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
| $170M | 6.56% |
2,236,701
| – | – |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $162M | 6.24% |
10,944,988
+1,988,000
| +22% | +$32.2M |
|
|
NXTM
3
DELISTED
NxStage Medical Inc.
NXTM
| $100M | 3.87% |
3,744,151
-514,045
| -12% | -$14.2M |
|
|
4
Gilead Sciences
GILD
$167B
| $81.7M | 3.15% |
+1,203,000
| New | +$84.6M |
|
5
Viatris
VTRS
$20.1B
| $79.6M | 3.07% |
2,042,224
+275,846
| +16% | +$11.1M |
|
|
DBVT
6
DBV Technologies
DBVT
$870M
| $61.4M | 2.37% |
174,323
| – | – |
|
|
PTLA
7
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $56.9M | 2.19% |
1,451,301
-3,203,146
| -69% | -$102M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $54.6M | 2.11% |
1,365,000
-477,415
| -26% | -$17.1M |
|
9
Elevance Health
ELV
$80.9B
| $52.6M | 2.03% |
318,000
| – | – |
|
|
GWPH
10
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $51.5M | 1.98% |
425,545
-502,647
| -54% | -$61.7M |
|
11
Centene
CNC
$32.8B
| $43M | 1.66% |
1,207,286
| – | – |
|
|
LCI
12
DELISTED
Lannett Company, Inc.
LCI
| $41.4M | 1.6% |
463,474
-38,414
| -8% | -$3.28M |
|
|
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
| $39.4M | 1.52% |
4,072,809
| – | – |
|
14
Editas Medicine
EDIT
$457M
| $38.2M | 1.47% |
1,709,400
| – | – |
|
|
NVRO
15
DELISTED
NEVRO CORP.
NVRO
| $37.8M | 1.46% |
402,998
-348,300
| -46% | -$31.5M |
|
|
AERI
16
DELISTED
Aerie Pharmaceuticals
AERI
| $36.1M | 1.39% |
795,743
-1,043,086
| -57% | -$46.5M |
|
|
AET
17
DELISTED
Aetna Inc
AET
| $34.1M | 1.31% |
267,000
+25,000
| +10% | +$3.14M |
|
|
18
McKesson
MCK
$98.5B
| $34M | 1.31% |
+229,000
| New | +$33.5M |
|
|
MNK
19
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $32.5M | 1.25% |
728,949
+321,949
| +79% | +$15.9M |
|
20
Vanda Pharmaceuticals
VNDA
$327M
| $32.2M | 1.24% |
2,299,046
-1,125,630
| -33% | -$16M |
|
21
eHealth
EHTH
$47.3M
| $31.8M | 1.23% |
2,640,609
| – | – |
|
|
LOXO
22
DELISTED
Loxo Oncology, Inc
LOXO
| $31.7M | 1.22% |
753,300
+502,300
| +200% | +$20.7M |
|
23
Xencor
XNCR
$1.3B
| $30.7M | 1.19% |
1,284,758
-735,242
| -36% | -$17.7M |
|
|
WBA
24
DELISTED
Walgreens Boots Alliance
WBA
| $29.6M | 1.14% |
355,957
| – | – |
|
|
UAM
25
DELISTED
Universal American Corp
UAM
| $28.3M | 1.09% |
2,833,531
-940,559
| -25% | -$9.36M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q1 2017 Portfolio in Review
As of Q1 2017, Deerfield Management held 118 positions worth $2.59B, up 6.7% from $2.43B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Deerfield Management withdrew a net $639M in Q1 2017, closing 12 positions and reducing 28 holdings. Its most notable exit was Zimmer Biomet, an estimated $15.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 69% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Gilead Sciences worth $81.7M.
- Deerfield Management's largest Q1 2017 buy was Gilead Sciences: 1,203,000 shares worth $81.7M.
- Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017, an estimated $32.2M increase.
- Deerfield Management's biggest Q1 2017 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $102M.
- Deerfield Management fully exited Zimmer Biomet in Q1 2017, selling an estimated $15.5M.
- Deerfield Management's ten largest holdings make up 35% of its $2.59B portfolio in Q1 2017.
- Deerfield Management opened 11 new positions and closed 12 in Q1 2017.
- Deerfield Management's portfolio value rose 6.7% quarter-over-quarter to $2.59B.
Based on Deerfield Management's 13F filing for Q1 2017, filed 15 May 2017.